For the Inventor, By the Inventor

Enter assignee name

Culver City, CA, United States of America

Nantcell, Inc.

USPTO Granted Patents = 49

CIPO Patents = 1

EPO Patents = 7

Trademarks = 2

Forward Citations = 34

Loading Chart...

Loading Chart...

35 inventors (with patents filed for the assignee):

Patrick Soon-Shiong (25 out of 475 patents)

Kayvan R Niazi (22 out of 99 patents)

Shahrooz Rabizadeh (15 out of 86 patents)

4. Hans G Klingemann (6 out of 47 patents)

5. Stephen Charles Benz (5 out of 57 patents)

6. Laurent H Boissel (5 out of 36 patents)

7. John H Lee (4 out of 13 patents)

8. Barry J Simon (4 out of 18 patents)

9. Mustafa Jaber (4 out of 22 patents)

10. Nicholas James Witchey (4 out of 160 patents)

11. Bing Song (3 out of 79 patents)

12. Jeffrey Safrit (3 out of 5 patents)

13. Christopher W Szeto (3 out of 14 patents)

14. Liudmila A Beziaeva (3 out of 11 patents)

15. Aaron Randolph Bassett (3 out of 4 patents)

Core Competencies:

T-cell Memory

Immunosuppressed Treatment

Neoepitope Vectors

HIV Treatment Compositions

COVID-19 Therapeutics

Deep Learning Models

Bacillus Calmette-Guerin

Patient-Specific Therapeutics

Electroporation Techniques

Tumor Evaluation

Personalized Vaccines

Immune Therapy

49 patents: Sort by Forward Citations

1. 12737880 - Systems and methods of analyzing microbiomes using artificial intelligence (2026-09-15),

2. 12734216 - TREATMENT OF IMMUNOSUPPRESSED SUBJECTS (2026-09-15),

3. 12730579 - Object storage and access management systems and methods (2026-09-08),

4. 12653874 - Nant cancer vaccine (2026-06-16),

5. 12580056 - Production and delivery tracking and sample verification of patient-specific therapeutics (2026-03-17),

6. 12571003 - Electroporation with active compensation (2026-03-10),

7. 12527865 - haNK cetuximab combinations and methods (2026-01-20),

8. 12491201 - Maximizing T-cell memory and compositions and methods therefor (2025-12-09),

9. 12427184 - Treatment of immunosuppressed subjects (2025-09-30),

10. 12311018 - Targeted neoepitope vectors and methods therefor (2025-05-27),

11. 12303552 - Treatment of immunosuppressed subjects (2025-05-20),

12. 12303477 - HIV treatment compositions and methods (2025-05-20),

13. 12297247 - Fusion molecules of CTLA4 and IL-15 (2025-05-13),

14. 12285481 - Methods for the treatment of COVID-19 comprising administering replication-defective adenoviruses encoding the SARS-CoV-2 spike glycoprotein and modified nucleocapsid protein (2025-04-29),

15. 12285480 - Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses (2025-04-29),

NantCell is a biotechnology company dedicated to revolutionizing cancer treatment through the development of innovative immunotherapies. With a focus on personalized therapies, NantCell aims to provide effective and targeted treatments for a wide range of cancer types. Leveraging cutting-edge technologies and a deep understanding of the immune system, NantCell is committed to improving patient outcomes and making significant advancements in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

49 Patents

#10 in Culver City, CA

#1,679 in California

#7,130 in US

#14,245 in the World

Culver City, CA, United States of America

Nantcell, Inc.

Forward Citations = 34

35 inventors:

Patrick Soon-Shiong (25 out of 475 patents)

Kayvan R Niazi (22 out of 99 patents)

Shahrooz Rabizadeh (15 out of 86 patents)

4. Hans G Klingemann (6 out of 47 patents)

5. Stephen Charles Benz (5 out of 57 patents)

Please report any incorrect information to [email protected]

Loading…